Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chubb
Boehringer Ingelheim
AstraZeneca
Deloitte
Cipla

Generated: August 22, 2019

DrugPatentWatch Database Preview

Patent: 9,550,827

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,550,827
Title:Methods for ameliorating and preventing central nervous system inflammation
Abstract: The invention provides compositions and methods for ameliorating, treating, reversing or preventing pathology or inflammation in the central nervous system (CNS), or the brain, caused or mediated by NFkB, IL-6, IL-6-R, NADPH oxidase (Nox), and/or superoxide and/or hydrogen peroxide production by a NADPH oxidase, including for example ameliorating, treating, reversing or preventing schizophrenia, psychosis, delirium, e.g., post-operative delirium, drug-induced psychosis, psychotic features associated with frailty syndrome (FS), aging, depression, dementias; traumatic war neurosis, post traumatic stress disorder (PTSD) or post-traumatic stress syndrome (PTSS), Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig\'s Disease), and/or Multiple Sclerosis (MS). The invention also provides methods for purifying a C60 fullerene, C.sub.3 (tris malonic acid C60) or malonic acid derivatives.
Inventor(s): Dugan; Laura L. (Brentwood, TN), Behrens; Maria Margarita (Del Mar, CA), Ali; Sameh S. (San Diego, CA)
Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)
Application Number:12/681,743
Patent Claims:see list of patent claims

Details for Patent 9,550,827

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech ACTEMRA tocilizumab INJECTABLE;INTRAVENOUS, SUBCUTANEOUS 125472 001 2013-10-21 ➤ Sign Up THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2028-10-18 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 003 2010-01-08 ➤ Sign Up THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2028-10-18 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 002 2010-01-08 ➤ Sign Up THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2028-10-18 RX search
Genentech ACTEMRA tocilizumab INJECTABLE; INJECTION 125276 001 2010-01-08 ➤ Sign Up THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA) 2028-10-18 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
Chinese Patent Office
Cantor Fitzgerald
Julphar
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.